Anthem Biosciences IPO to Open on July 14; Price Band Set at ₹540–₹570

From Vision to Valuation: Ajay Bhardwaj and Muhammed Gawir Baig Chart Anthem’s IPO Journey

Anthem’s differentiated positioning in biosciences and its track record of delivery make this a compelling opportunity for all categories of investors

With a clear regulatory framework, strong leadership, and market expansion potential, the company is well-aligned for sustained market performance post-listing

 

BILKULONLINE
By Rafat Quadri

Contract research and manufacturing company Anthem Biosciences is launching its Initial Public Offering (IPO) on Monday, July 14, 2025. The issue is entirely an Offer for Sale (OFS), where promoters and existing investors will sell up to 59.6 million shares, amounting to ₹3,395 crore.

Ahmedabad, July 11: Bengaluru-based biopharmaceutical player Anthem Biosciences Limited is set to launch its much-anticipated Initial Public Offering (IPO) on Monday, July 14, 2025, with the price band fixed at ₹540 to ₹570 per equity share of face value ₹2 each. The IPO will close on Wednesday, July 16, 2025, while the Anchor Investor bidding will open on Friday, July 11, 2025.

The public issue is entirely an Offer for Sale (OFS), aggregating up to ₹33,950 million, with participation from key stakeholders including Ganesh Sambasivam, K Ravindra Chandrappa, Viridity Tone LLP, Portsmouth Technologies LLC, and others. Additionally, ₹82.5 million worth of shares are reserved for eligible employees, who will also receive a ₹50 per share discount under the Employee Reservation Portion.

Ajay Bhardwaj, Chairman, Managing Director & CEO of Anthem Biosciences, addressed media in Ahmedabad at the launch event, emphasizing the company’s strategic focus and vision.

“This IPO is a milestone in our journey of innovation-led growth. Anthem Biosciences is poised to scale new heights in contract research and manufacturing services,” he said. “Ahmedabad holds a special place for us—it’s a city with a thriving entrepreneurial spirit and a deep-rooted pharma ecosystem,” he added.

The company operates in the high-growth segment of contract development and manufacturing, catering to global pharmaceutical and biotech clients.

“We are deeply committed to scientific excellence and global standards. Our listing will allow us to further strengthen capabilities and broaden our global outreach,” Bhardwaj noted.

Muhammed Gawir Baig, Chief Financial Officer, highlighted the company’s robust fundamentals:

“Anthem has shown consistent revenue growth and strong profitability. We believe this offering will reinforce our financial foundation and open new avenues for global partnerships.”

“We’ve built a robust and scalable business model. Investors looking at long-term value creation will see the strength in our numbers and strategy.”

The IPO will be conducted through the Book Building Process as per SEBI’s guidelines. Not more than 50% of the issue will be allocated to Qualified Institutional Buyers (QIBs), at least 15% to Non-Institutional Investors (NIIs), and not less than 35% to Retail Individual Investors (RIIs).

Prachi Malkan, who represents the Equity Capital Markets team, said “We’ve seen strong early interest, especially from marquee institutional investors. The price band reflects both investor appetite and the company’s valuation strength.”

“Anthem’s differentiated positioning in biosciences and its track record of delivery make this a compelling opportunity for all categories of investors.”

All non-anchor investors will have to apply using the Application Supported by Blocked Amount (ASBA) mechanism, and eligible retail investors can apply with a minimum bid of 26 equity shares and in multiples thereafter. The equity shares are proposed to be listed on BSE and NSE.

JM Financial Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited, and Nomura Financial Advisory and Securities (India) Private Limited are the Book Running Lead Managers (BRLMs) to the offer.

For more details, investors can refer to the Red Herring Prospectus (RHP) dated July 8, 2025.

(Rafat Quadri can be contacted at editorbilkul@gmail.com)

• Kindly Like the shared links and Subscribe BILKULONLINE channel. Thanks
• https://youtu.be/jBM54gIOHic
• https://youtu.be/YCqq3M2sfL8
• https://youtube.com/shorts/2Ep-UjqgN_o?feature=share
• https://youtube.com/shorts/yrFGVjWJVu0?feature=share
• https://youtube.com/shorts/QXApzziOkxQ?feature=share